Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

2.

Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma.

García-Cosío M, Santón A, Martín P, Camarasa N, Montalbán C, García JF, Bellas C.

Mod Pathol. 2004 Dec;17(12):1531-8.

3.

B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.

Herbeck R, Teodorescu Brînzeu D, Giubelan M, Lazăr E, Dema A, Ioniţă H.

Rom J Morphol Embryol. 2011;52(1):69-74.

4.

Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas.

Sáez AI, Artiga MJ, Sánchez-Beato M, Sánchez-Verde L, García JF, Camacho FI, Franco R, Piris MA.

Mod Pathol. 2002 Mar;15(3):211-20.

5.
6.

Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers.

Nam-Cha SH, Montes-Moreno S, Salcedo MT, Sanjuan J, Garcia JF, Piris MA.

Mod Pathol. 2009 Aug;22(8):1006-15. doi: 10.1038/modpathol.2009.54. Epub 2009 May 22.

7.

Clusterin expression in malignant lymphomas: a survey of 266 cases.

Saffer H, Wahed A, Rassidakis GZ, Medeiros LJ.

Mod Pathol. 2002 Nov;15(11):1221-6.

8.

Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.

Cho RJ, McCalmont TH, Ai WZ, Fox LP, Treseler P, Pincus LB.

J Cutan Pathol. 2012 Jun;39(6):651-8. doi: 10.1111/j.1600-0560.2012.01872.x. Epub 2012 Feb 11.

PMID:
22324490
9.

Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease.

Marafioti T, Mancini C, Ascani S, Sabattini E, Zinzani PL, Pozzobon M, Pulford K, Falini B, Jaffe ES, Müller-Hermelink HK, Mason DY, Pileri SA.

Haematologica. 2004 Aug;89(8):957-64.

10.
11.

Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.

Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J.

Oncogene. 2003 Feb 20;22(7):964-73.

PMID:
12592383
13.

Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.

Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A, Bagdi E, Kehrl JH, Jaffe ES, Raffeld M.

Blood. 1998 Aug 15;92(4):1308-16.

14.

Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.

Coupland SE, Loddenkemper C, Smith JR, Braziel RM, Charlotte F, Anagnostopoulos I, Stein H.

Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64.

PMID:
16249468
15.

Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.

Loddenkemper C, Anagnostopoulos I, Hummel M, Jöhrens-Leder K, Foss HD, Jundt F, Wirth T, Dörken B, Stein H.

J Pathol. 2004 Jan;202(1):60-9.

PMID:
14694522
17.

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.

Nguyen PL, Harris NL, Ritz J, Robertson MJ.

Am J Pathol. 1996 Mar;148(3):847-53. Erratum in: Am J Pathol 1996 Jul;149(1):346.

18.

T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma.

Dorfman DM, Hwang ES, Shahsafaei A, Glimcher LH.

Hum Pathol. 2005 Jan;36(1):10-5.

PMID:
15712176
19.
20.

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R.

J Clin Pathol. 2007 Jun;60(6):709-14. Epub 2006 Jul 12.

Supplemental Content

Support Center